Core Insights - Outbrain Inc. reported strong financial results for Q1 2025, achieving guidance on Ex-TAC gross profit and Adjusted EBITDA, with CTV revenues growing over 100% year-over-year on a pro forma basis [1][2] - The company completed the acquisition of Teads for approximately $900 million, which is expected to yield significant synergies and integration benefits [4][21] - Full-year guidance for 2025 remains positive, with expectations for continued growth and strategic partnerships [6][7] Financial Performance - Revenue for Q1 2025 was $286.4 million, a 32% increase from $217.0 million in Q1 2024 [2][5] - Gross profit reached $82.7 million, up 99% from $41.6 million in the prior year, with a gross margin increase to 28.9% [2][5] - Ex-TAC gross profit was $103.1 million, a 98% increase year-over-year, with an Ex-TAC gross margin of 36.0% [2][5] - The net loss for the quarter was $54.8 million, compared to a net loss of $5.0 million in Q1 2024, influenced by acquisition-related costs and restructuring charges [2][5] Business Highlights - The integration of Teads is on track, with expected synergies of $65 million to $75 million by 2026, including $40 million in cost synergies for 2025 [4][6] - The company has initiated cross-selling of legacy Outbrain solutions to Teads' enterprise brand customers, with several campaigns already sold [4] - New strategic partnerships have been established with major brands such as Ferrero and Philip Morris International [4] Guidance and Future Outlook - For Q2 2025, the company expects revenue of $286.4 million, with continued strong adoption of its Moments vertical video offering [6] - Full-year guidance for 2025 includes Ex-TAC gross profit expectations of $141 million to $150 million and Adjusted EBITDA of $26 million to $34 million [6][7] - The company is focused on leveraging predictive AI technology to enhance its advertising platform and drive business outcomes [21]

Core Viewpoint - Altria Group has maintained a strong dividend history, raising its dividend annually since 2009, with a current forward yield of 7%, but concerns exist regarding the sustainability of this dividend amid declining cigarette volumes and competition from alternative products [1][11]. Revenue and Volume Analysis - Cigarette smoking in the U.S. is declining due to health concerns and the rise of alternatives like vaping, with Altria's cigarette shipment volumes down 13.7% in Q1, including a 13.3% drop for Marlboro and a 24.9% plunge in discount brand shipments [2][3]. - Revenue from the smokeable segment fell 4.1% to $3.91 billion, although adjusted operating income rose 2.7% due to lower manufacturing costs [4]. - In the oral tobacco segment, shipment volumes decreased by 5% to 175.4 million cans, with overall revenue rising by 0.5% to $654 million, but adjusted operating income remained flat [5]. - Altria's Njoy vaping business saw consumable shipments increase by 23.9% to 13.5 million units, but device shipments fell 70% to 0.3 million units, indicating a mixed performance in the vaping segment [6]. Financial Health and Dividend Safety - Altria generated $2.72 billion in operating cash flow and $2.68 billion in free cash flow in the quarter, with a dividend payout of $1.73 billion, resulting in a coverage ratio of over 1.5 times based on free cash flow [9]. - The company ended the quarter with net debt of $21.3 billion and a leverage ratio of 1.7 times, indicating manageable debt levels [9]. Future Outlook - Altria maintained its full-year guidance for adjusted EPS between $5.30 and $5.45, reflecting growth of 2% to 5%, while acknowledging the impact of increased tariffs and cost inflation on consumer behavior [7]. - There are concerns that continued price increases may not be sustainable in the face of declining volumes, which could affect long-term profitability [10][12]. Market Position and Valuation - Altria's stock has performed well in a volatile market, but the overall cigarette business is declining, and its smoke-free products are not yet significant enough to offset this trend [11]. - The company trades at a forward P/E ratio of 11 based on 2025 analyst consensus, which is higher than British American Tobacco but lower than Philip Morris International, which is experiencing growth without facing similar volume declines [13].

Core Viewpoint - British American Tobacco (BAT) is emerging from a challenging decade and is positioned to potentially outperform the market moving forward, despite the inherent risks associated with tobacco investments [1][2][3]. Company Performance - BAT has faced significant challenges over the past decade, including a tumultuous market environment and the consequences of a costly merger with Reynolds American, which resulted in a $31.5 billion non-cash write-down on its U.S. cigarette brands in late 2023 [3][10]. - The stock has shown a 43% increase over the past year, although it remains down 25% from a decade ago, indicating a potential shift in market sentiment towards a more favorable outlook for the company [11]. Revenue and Growth - BAT's new category products, including electronic cigarettes and heated tobacco, have seen organic, currency-neutral sales growth of 8.9% in 2024, contributing to 17.5% of total revenue [4]. - Management anticipates annualized currency-neutral revenue growth of 3% to 5% starting in 2026, which, while modest, represents a recovery path from previous declines [5]. Dividend and Cash Flow - The company offers a nearly 7% dividend yield, providing attractive short-term returns, especially during periods of market volatility [2][6]. - In 2024, BAT generated £7.9 billion in free cash flow and paid out £5.2 billion in dividends, resulting in a payout ratio of 66%, indicating a healthy cash flow position [8]. Valuation and Market Position - BAT's stock valuation has improved, currently trading at under 10 times 2025 earnings estimates, which is a significant recovery from a low of under 8 times earnings early last year [12]. - The company’s strategic focus on transitioning to smoke-free products positions it favorably against competitors, although it still trails Philip Morris International in this area [4][10].

Core Viewpoint - Altria remains an attractive investment for income investors due to its long history of dividend increases and its current high dividend yield of 7% [1][14] Company Strategy - Altria has faced challenges over the past decade due to declining smoking rates and strategic missteps, including a $12 billion investment in Juul and a failed investment in Cronos Group [5] - The company has shifted focus to smoke-free products, selling the rights to market Iqos back to Philip Morris International and investing in Njoy, which has received FDA marketing authorization for its pod-based e-vapor product [6][8] - Altria's next-gen portfolio includes on!, an oral nicotine pouch, and a new heated tobacco product called Ploom, developed in partnership with JT Group [7] Market Performance - Njoy's consumables saw a 15.3% increase to 12.8 million units, and device shipments rose 22.2% to 1.1 million, with retail market share nearly doubling to 6.4% [8] - Despite Njoy's growth, cigarettes still account for the majority of Altria's revenue, with volume sales declining from 76.4 million in 2023 to 68.6 million in 2024, while smokeable products represented 88% of revenue in 2024 [9] Future Goals - Altria aims for a mid-single digits adjusted earnings per share (EPS) compound annual growth rate (CAGR) off $4.84 in 2022, with adjusted EPS rising 3.4% to $5.12 in 2024, resulting in a 2.9% CAGR over the last two years [10] - The company plans to increase its dividend by mid-single digits annually, following a 4.1% increase in 2024, and targets a debt-to-EBITDA ratio of 2, currently at 2.1 [11] - Altria expects to maintain an adjusted operating margin of at least 60% through 2028, although it has struggled to meet growth targets and has adjusted its expectations for Njoy's cash flow contributions [12] Investment Outlook - Altria's stock trades at a price-to-earnings ratio of 12, with a 7% dividend yield, indicating potential for success even if not all 2028 goals are met [13] - In the current economic climate, Altria is positioned to potentially outperform the S&P 500, benefiting from its status in the consumer staples sector and the consistent demand for its products [14] - Overall, despite declining cigarette consumption, Altria is expected to be in a better position three years from now [15]

Core Insights - ArcStone Securities and Investments Corp. serves as the exclusive financial advisor to Mangoceuticals Inc. in its acquisition of Smokeless Technology Corp., marking Mangoceuticals' entry into the high-growth oral stimulant pouch sector [1][2][3] - The acquisition enhances Mangoceuticals' capabilities in the consumer-packaged goods sector, targeting various demographics including athletes and Gen Z consumers seeking healthier alternatives [3][6] - The transaction is expected to position Mangoceuticals as a leader in the next-generation health and wellness delivery market, leveraging Smokeless Tech's intellectual property and formulations [6][7] Company Overview - Mangoceuticals Inc. is focused on launching high-impact pouches and aims to disrupt traditional wellness delivery methods with "better-for-you" energy solutions [6][7] - The company is set to benefit from the expertise of Tim Corkum, a veteran from Philip Morris International, who will lead the new Pouch Division [4][5] - The acquisition positions Mangoceuticals as one of the few public companies in the functional wellness and oral delivery market, appealing to both institutional and retail investors [8] Strategic Implications - The deal signifies a transformational step for Mangoceuticals, aligning with the trend towards on-the-go, clinically informed wellness solutions [7] - ArcStone's role underscores its expertise in cross-border M&A, particularly in the health and wellness sectors, enhancing its reputation in the financial advisory landscape [3][9] - The combined entity will focus on sourcing disruptive ingredients and proprietary formulations, aiming to lead in the wellness delivery category [6][7]

Core Viewpoint - Altria Group is positioned as a stable investment option during market uncertainty, offering consistent dividend income and potential growth in its smoke-free product segment [2][10]. Financial Performance - Altria's net revenue after excise taxes increased by 1.6% year-over-year to $5.1 billion, despite an 8% decline in cigarette sales volume [3]. - The smokeables division generated an operating income of $10.8 billion in 2024, with a 60% operating margin, highlighting its profitability [3]. Product Strategy - Altria aims to double its smoke-free product sales to $5 billion by 2028, although it currently lags behind competitors like Philip Morris International [4]. - The company is focusing on expanding its smoke-free product offerings, including nicotine pouches and electronic vaping [4]. Capital Returns and Dividends - Altria has reduced its shares outstanding by 14% over the last 10 years, with accelerated buybacks in 2024 [6]. - The dividend per share has increased by approximately 100% over the past decade, with a current quarterly payout of $1.02 [6]. - Management plans to grow the dividend per share at a mid-single-digit percentage rate annually, around 5% through 2028 [7]. Investment Rationale - Investing $1,000 in Altria Group stock is projected to yield around $70 in annual dividend income based on the current yield [9]. - The company has demonstrated a 103% growth in free cash flow per share over the last 10 years, providing a solid foundation for future dividend increases [9][10].

Core Insights - Altria is facing significant challenges as cigarette demand declines, which is its primary revenue source, while management emphasizes potential opportunities that may indicate the company is lagging behind [1][10] Business Overview - Altria's main business revolves around cigarette sales, which constituted 88% of its revenues in 2024, with cigarettes making up nearly 98% of smokeable tobacco volumes [2] Financial Performance - Cigarette volumes have been declining for years, with a notable drop of 10.2% in 2024; however, price increases have mitigated revenue losses, resulting in a 1.3% revenue decline and a 3.4% rise in adjusted earnings [3] - The company raised its dividend in 2024, reflecting a high dividend yield of approximately 7%, which attracts dividend investors despite the negative trends in its core business [4] Market Trends - The number of smokers in the U.S. decreased from 34 million in 2019 to 28 million in 2024, while non-combustible product users remained stable at around 8 million; however, non-combustible-only consumers surged from 11 million to 18 million, marking a 60% growth [5][6] Strategic Missteps - Altria has made several strategic errors, including spinning off Philip Morris International, which left it vulnerable in a declining cigarette market and created new competition in the non-combustible space [7] - Investments in Juul and a marijuana company resulted in significant write-offs, and while the recent acquisition of NJOY shows better sales performance, it faces patent litigation with Juul [8] Growth Opportunities - Non-combustible products are increasingly important, yet Altria has not capitalized on this trend, with non-smokeable products accounting for only 11.7% of revenues in 2024, down from 12.4% in 2019, despite the non-combustible category growing significantly [9][10]

Perhaps not surprisingly, defensive stock Philip Morris International ( PM ) has been one of the best-performing US companies this year. When I initially covered the stock in November 2024, I argued that it was a best-in-class defensive stock with strongI am an investment professional with a background in both equity and real estate markets. I specialize in identifying long-only opportunities that offer safe and growing dividends, aiming to outperform the broader market on a risk-adjusted return basis. In a ...

Core Insights - Philip Morris International (NYSE: PM) has experienced a significant increase of 66% over the past year, outperforming NVIDIA's (NVDA) 12-month returns amidst a broader market trend [1]. Company Performance - The stock performance of Philip Morris International has been notably strong, with a 66% rise in value over the last year, indicating robust investor interest and confidence in the company's future prospects [1]. Market Context - The current market environment shows a shift in investor focus, with analysts primarily concentrating on AI technologies, yet Philip Morris is achieving substantial returns that surpass those of major tech companies like NVIDIA [1].

Core Viewpoint - The article compares Altria and Philip Morris International, highlighting their differing business models, financial performance, and growth prospects in the tobacco industry, particularly in the context of their transitions to smoke-free products. Business Model Comparison - Altria and Philip Morris, despite sharing cigarette brands, have different business models, with Altria focusing on the U.S. market and Philip Morris on international markets [2][3] - Philip Morris has successfully developed next-generation products like Iqos and Zyn, gaining significant market share, while Altria has struggled with its investments in Juul and cannabis [4][5][6] Financial Performance - In 2024, Altria's revenue declined by 1.9% to $24 billion, primarily due to a 10.2% drop in cigarette shipment volume, although it maintained a high adjusted operating margin of 61.2% [8][9] - Philip Morris reported a 7.7% increase in revenue to $37.9 billion, with a 0.6% rise in international cigarette volume and a 16% increase in operating income [9] Dividend and Valuation - Altria offers a dividend yield of 7% and trades at a price-to-earnings ratio of 11.3, maintaining a strong reputation as a dividend payer [10][11] - Philip Morris has a lower dividend yield of 3.5% but a higher P/E ratio of 22, reflecting its faster growth and success in next-gen products [11] Growth Prospects - Altria is beginning to see growth from its investment in Njoy, but it continues to face revenue losses and challenges in its core cigarette business [12] - Philip Morris is experiencing growth in both its next-gen products and its cigarette business, indicating a more favorable long-term growth trajectory [12][13]